SCHEMBL4297568

SCHEMBL4297568

COCc1nc(NC(C)=O)sc1C(=O)Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.47
HPGD P15428 1/20 0.47
DYRK1A Q13627 7/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP2C19 P33261 2/20 0.41
MAPT P10636 2/20 0.41
CYP3A4 P08684 1/20 0.41
HTT P42858 1/20 0.41
KDM4E B2RXH2 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 3/20 0.40
MEN1 O00255 2/20 0.40
CYP2C9 P11712 1/20 0.40
RXFP1 Q9HBX9 1/20 0.38
PIK3CG P48736 2/20 0.37
PIK3CA P42336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4291781 0.87 ALDH1A1 (0.48) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL4294136 0.79 ALDH1A1 (0.42) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL9048861 0.73 SMN1; SMN2 (0.46) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL6198592 0.71 ALDH1A1 (0.47) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL11163768 0.70 KMT2A (0.49) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL27459154 0.69 ALDH1A1 (0.47) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL4969363 0.69 PIK3CG (0.43) ALDH1A1HPGDDYRK1ASMN1; SMN2NPC1
SCHEMBL3936427 0.69 ALDH1A1 (0.70) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL2835357 0.67 RXFP1 (0.70) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A
SCHEMBL1743735 0.67 ALDH1A1 (0.39) ALDH1A1HPGDSMN1; SMN2NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1981884-B1 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS AMGEN INC (US) 2012-06-13 EP disclosed
US-8084479-B2 Thiazole compounds and methods of use AMGEN INC. (US) 2011-12-27 US disclosed
US-20090270445-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2009-10-29 US disclosed
CN-101421265-A Thiazole compounds as protein kinase b (pkb) inhibitors AMGEN INC (US) 2009-04-29 CN disclosed
US-7514566-B2 Thiazole compounds and methods of use AMGEN, INC. (US) 2009-04-07 US disclosed
EP-1981884-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B (PKB) INHIBITORS Amgen, Inc (US) 2008-10-22 EP disclosed
WO-2007084391-A2 THIAZOLE COMPOUNDS AS PROTEIN KINASE B ( PKB) INHIBITORS AMGEN INC. (US) 2007-07-26 WO disclosed
US-20070173506-A1 Thiazole compounds and methods of use AMGEN INC. (US) 2007-07-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270445-A1 Thiazole compounds and methods of use MTOR, JAK2, TK2 ALDH1A1 2019/4885HPGD 1238/4885DYRK1A 2626/4885
US-20070173506-A1 Thiazole compounds and methods of use MTOR, JAK2, PCK2 ALDH1A1 2061/4885HPGD 1625/4885DYRK1A 2896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.